Current Place of SGLT2i in the Management of Heart Failure: An Expert Opinion from India.

H K Chopra,Tiny Nair,G S Wander,C K Ponde,Saumitra Ray,Dinesh Khullar,Navin C Nanda,Jagat Narula,Ravi R Kasliwal,D S Rana,Ashok Kirpalani,J P S Sawhney,Praveen Chandra,Yatin Mehta,Viveka Kumar,S Tewari,A K Pancholia,Vijay Kher,Sandeep Bansal,Sanjay Mittal,Praful Kerkar,P K Sahoo,Ramesh Hotchandani,Sunil Prakash,Nagendra Chauhan,Vishal Rastogi,A Jabir,S Shanmugasundaram,Mangesh Tiwaskar,Ajay Sinha,Vittul Gupta,S S Mishra,S N Routray,A K Omar,Onkar C Swami,Aparna Jaswal,Shamsad Alam,Rajeev Passey,Rajeeve Rajput,Justin Paul,Aditya Kapoor,D Prabhakar,Subhash Chandra,Poonam Malhotra,Vivudh Pratap Singh,Manish Bansal,Priyank Shah,Sanjay Jain,Mohan Bhargava,I B Vijayalakshmi,Kiron Varghaese,Dharmender Jain,Anupam Goel,Kiran Mehmood,Namrata Gaur,Rohit Tandon,Asha Moorthy,Sheeba George,V K Katyal,R R Mantri,Rahul Mehrotra,Dilip Bhalla,Vinod Mittal,Sarita Rao,Manish Jagia,Harmeet Singh,Surabhi Awasthi,Ameet Sattur,Rekha Mishra,Anand Pandey,Rajeev Chawla,Shalini Jaggi,Blessy Sehgal,Alok Sehgal,Naresh Goel,Ripen Gupta,Samir Kubba,Abhinav Chhabra,Saurabh Bagga,N R Shastry

doi:10.59556/japi.71.0440

Abstract

Heart failure (HF) is a global health concern that is prevalent in India as well. HF is reported at a younger age in Indian patients with comorbidity of type 2 diabetes (T2DM) in approximately 50% of patients. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), originally approved for T2DM, are new guideline-recommended and approved treatment strategies for HF. Extensive evidence highlights that SGLT2i exhibits profound cardiovascular (CV) benefits beyond glycemic control. SGLT2i, in conjunction with other guideline-directed medical therapies (GMDT), has additive effects in improving heart function and reducing adverse HF outcomes. The benefits of SGLT2i are across a spectrum of patients, with and without diabetes, suggesting their potential place in broader HF populations irrespective of ejection fraction (EF). This consensus builds on the updated evidence of the efficacy and safety of SGLT2i in HF and recommends its place in therapy with a focus on Indian patients with HF.

Full Text